Skip to main content

Table 2 Use of antibacterials for systemic use (ATC J01) used for prevention or treatment in Polish and all European group in Healthcare-Associated Infections in Long-Term Care Facilities Project (HALT-3), 2016–2017

From: Antibiotic consumption in long-term care facilities in Poland and other European countries in 2017

Antibacterials for systemic use, anatomical therapeutic chemical classification

HALT PPS (n;%) [9]

Total

Poland

N (%)

AMC**

N (%)

AMC**

Tetracyclines, J01A

105 (2.1)

1.03

1 (1.4)

0.44

Amphenicols, J01B

2 (0.0)

0.02

0 (0.0)

0.00

Beta-lactams, penicillins, J01C

1515 (29.8)

14.81

20 (27.4)

8.77

Other beta-lactams, J01D

639 (12.6)

6.25

16 (21.9)

7.01

Sulfonamides and trimethoprim, J01E

724 (14.2)

7.08

3 (4.1)

1.32

Macrolides, lincosamides and streptogramins, J01F

369 (7.3)

3.61

3 (4.1)

1.32

Aminoglycosides, J01G

34 (0.7)

0.33

5 (6.8)

2.19

Quinolones, J01M

752 (14.8)

7.35

12 (16.4)

5.26

Combinations of antibacterials, J01R

9 (0.2)

0.09

0 (0.0)

0.00

Other antibacterials, J01X*

939 (18.5)

9.18

13 (17.8)

5.70

Total

5.088 (100.0)

49.74

73 (100.0)

32.00

  1. AMC antimicrobial consumption, calculated by dividing the number of residents on antimicrobials on the day of survey by the total number of residents in LTCFs on the day of survey and multiplying by 100; HALT PPS Healthcare-Associated infections (HAIs) and antimicrobial use in Long-term care facilities Point Prevalence Survey; n number of prescriptions;
  2. *Including: glycopeptides (J01XA), polymyxins (J01XB), steroid antibacterials (J01XC), imidazole derivatives (J01XD), nitrofuran derivatives (J01XE), others (J01XX)
  3. **Antimicrobial consumption (AMC) calculated per 1000 residents, expressed as: (total number of residents on antimicrobials on the day of survey/total number of residents in LTCF on the day of survey) × 1000
  4. ***n/a non applicable